Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2016 - 2025)
Historic Asset Utilization Ratio for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.12.
- Lineage Cell Therapeutics' Asset Utilization Ratio rose 3708.45% to 0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12, marking a year-over-year increase of 3708.45%. This contributed to the annual value of 0.09 for FY2024, which is 1137.13% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Asset Utilization Ratio stood at 0.12 for Q3 2025, which was up 3708.45% from 0.11 recorded in Q2 2025.
- Lineage Cell Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.47 during Q3 2022, with a 5-year trough of 0.01 in Q2 2021.
- For the 5-year period, Lineage Cell Therapeutics' Asset Utilization Ratio averaged around 0.15, with its median value being 0.09 (2024).
- As far as peak fluctuations go, Lineage Cell Therapeutics' Asset Utilization Ratio soared by 307823.0% in 2022, and later plummeted by 8287.2% in 2023.
- Lineage Cell Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.35 in 2021, then crashed by 66.82% to 0.12 in 2022, then decreased by 25.17% to 0.09 in 2023, then rose by 4.86% to 0.09 in 2024, then skyrocketed by 32.4% to 0.12 in 2025.
- Its Asset Utilization Ratio was 0.12 in Q3 2025, compared to 0.11 in Q2 2025 and 0.08 in Q1 2025.